ENDPOINTS

DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor in China

Plus, news about Palatin, Spero and BioAtla: DBV Technologies’ $306M financing: The French biotech could get up to that amount to help advance its peanut allergy patch for children through an ...

Mar 28, 2025 - 15:03
 0
DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor in China
Plus, news about Palatin, Spero and BioAtla: DBV Technologies’ $306M financing: The French biotech could get up to that amount to help advance its peanut allergy patch for children through an ...
Read More

Tags:

Previous Article

Meet the astronauts of SpaceX's Fram2 mission, the 1st to fly over Earth's poles

Next Article

Healthcare’s Security Paradox: Most Targeted, Least Prepared

Related Posts

Exclusive: CRISPR delivery startup Spotlight Therapeutics shuts down

Exclusive: CRISPR delivery startup Spotlight Therapeuti...

Feb 19, 2025  0

Mineralys’ Phase 3 blood pressure pill data support potential FDA approval

Mineralys’ Phase 3 blood pressure pill data support pot...

Mar 10, 2025  0

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

After Phase 3 depression setback, Neumora pauses two tr...

Mar 3, 2025  0